TFC

A major bank is cutting 205 jobs and shutting down its auto‑finance office, ending a decades‑old lending line. The move signals a shift away from that business segment.

The San Diego company is developing a dual GLP‑1/GIP drug that could be given as a shot or later as a pill, aiming to compete with Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy. The stock rose 36% after Oppenheimer raised its target.

On September 2, 2026, Ollie’s Bargain Outlet Holdings, Inc. (NASDAQ:OLLI) reported second-quarter results for the period ended August 1, 2026. Adjusted earnings per share jumped 43.4% to $1.42, while comparable store sales fell 1.8% and net sales rose 9.1% to $741.3 million on new store growth. Management cut its full-year comparable sales outlook to flat-to-0.5% […]

Vertex reported mid‑stage trial results for its experimental pill, inaxaplin, in patients with APOL1‑mediated kidney disease. The news helped lift the stock.

Analysts have raised Eli Lilly’s fair value estimate from $1,297.31 to $1,325.39, reflecting confidence in its GLP‑1 growth. The company’s stock remains closely watched by analysts.